98 related articles for article (PubMed ID: 20155222)
1. Biomarker update for breast, colorectal and non-small cell lung cancer.
Ross JS
Drug News Perspect; 2010; 23(1):82-8. PubMed ID: 20155222
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer.
Reuben JM; Lee BN; Li C; Gao H; Broglio KR; Valero V; Jackson SA; Ueno NT; Krishnamurthy S; Hortobagyi GN; Cristofanilli M
Breast J; 2010; 16(3):327-30. PubMed ID: 20408820
[No Abstract] [Full Text] [Related]
4. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
[No Abstract] [Full Text] [Related]
5. [Prognostic factors in breast cancer patients].
Roisman I; Peretz T; Reznick AZ; Lifshitz I; Bitterman A; Fares F; Toledano H; Barzilay A; Durst AL
Harefuah; 1996 May; 130(10):693-9. PubMed ID: 8794662
[No Abstract] [Full Text] [Related]
6. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
7. Triple negative, basal cell type and EGFR positive invasive breast carcinoma in Kuwaiti and British patients.
Ayad E; Francis I; Peston D; Shousha S
Breast J; 2009; 15(1):109-11. PubMed ID: 19077133
[No Abstract] [Full Text] [Related]
8. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic and predictive factors in breast cancer].
Bozhok AA; Semiglazov VF; Semiglazov VV; Arzumanov AS; Klettsel' AE
Vopr Onkol; 2005; 51(4):434-43. PubMed ID: 16308974
[TBL] [Abstract][Full Text] [Related]
11. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
[TBL] [Abstract][Full Text] [Related]
12. Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.
Le Goff JM; Lavayssière L; Rouëssé J; Spyratos F
Anticancer Res; 2000; 20(3B):2213-8. PubMed ID: 10928180
[TBL] [Abstract][Full Text] [Related]
13. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
14. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma.
Shepherd FA; Tsao MS
J Clin Oncol; 2010 Feb; 28(6):903-5. PubMed ID: 20100955
[No Abstract] [Full Text] [Related]
16. [Biological features of breast cancer in patients under 35].
Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer.
Iwase H; Itoh Y; Kuzushima T; Yamashita H; Iwata H; Toyama T; Hara Y; Kobayashi S
Cancer Detect Prev; 1997; 21(1):29-35. PubMed ID: 9043760
[TBL] [Abstract][Full Text] [Related]
18. Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program.
Hung T; Wolber R; Garratt J; Kalloger S; Gilks CB
Pathology; 2010 Dec; 42(7):637-42. PubMed ID: 21080872
[TBL] [Abstract][Full Text] [Related]
19. Male breast cancer: pathological and immunohistochemical features.
Willsher PC; Leach IH; Ellis IO; Bell JA; Elston CW; Bourke JB; Blamey RW; Robertson JF
Anticancer Res; 1997; 17(3C):2335-8. PubMed ID: 9245247
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer.
Miura N; Nakamura H; Sato R; Tsukamoto T; Harada T; Takahashi S; Adachi Y; Shomori K; Sano A; Kishimoto Y; Ito H; Hasegawa J; Shiota G
Cancer Sci; 2006 Dec; 97(12):1366-73. PubMed ID: 17052260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
